BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 35, Issue 13, 2017, Pages 1437-1443

  Woyach, Jennifer A ^a   Ruppert, Amy S ^a   Guinn, Daphne ^a   Lehman, Amy ^a   Blachly, James S ^a   Lozanski, Arletta ^a   Heerema, Nyla A ^a   Zhao, Weiqiang ^a   Coleman, Joshua ^a   Jones, Daniel ^a   Abruzzo, Lynne ^a   Gordon, Amber ^a   Mantel, Rose ^a   Smith, Lisa L ^a   McWhorter, Samantha ^a   Davis, Melanie ^a   Doong, Tzyy Jye ^a   Ny, Fan ^a   Lucas, Margaret ^a   Chase, Weihong ^a   Jones, Jeffrey A ^a   Flynn, Joseph M ^a   Maddocks, Kami ^a   Rogers, Kerry ^a   Jaglowski, Samantha ^a   Andritsos, Leslie A ^a   Awan, Farrukh T ^a   Blum, Kristie A ^a   Grever, Michael R ^a   Lozanski, Gerard ^a   Johnson, Amy J ^a   Byrd, John C ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; IBRUTINIB; OFATUMUMAB; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PHOSPHOLIPASE C GAMMA; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; FEMALE; FOLLOW UP; GENE DELETION; GENE MUTATION; HUMAN; IN SITU HYBRIDIZATION; INCIDENCE; KARYOTYPING; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; RISK FACTOR; SEQUENCE ANALYSIS; TRISOMY 12; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PHOSPHOLIPASE C GAMMA; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 85018308247     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.2282     Document Type: Article

References (15)

1. Herman SE, Gordon AL, Hertlein E, et al: Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117:6287-6296, 2011
2. Herman SE, Mustafa RZ, Gyamfi JA, et al: Ibrutinib inhibits BCR and NF-kB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood 123:3286-3295, 2014
3. Woyach JA, Bojnik E, Ruppert AS, et al: Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 123:1207-1213, 2014
4. Fowler N, Sharman JP, Smith SM, et al: The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: Results from a phase I study. Blood 116:964, 2010 (abstr)
5. Byrd JC, Brown JR, O'Brien S, et al: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213-223, 2014
6. Burger JA, Tedeschi A, Barr PM, et al: Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373:2425-2437, 2015
7. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl JMed 370:2286-2294, 2014
8. Maddocks KJ, Ruppert AS, Lozanski G, et al: Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1:80-87, 2015
9. Cheng S, Guo A, Lu P, et al: Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: Exploration of alternative kinase inhibitors. Leukemia 29:895-900, 2015
10. Furman RR, Cheng S, Lu P, et al: Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med 370:2352-2354, 2014
11. Liu TM, Woyach JA, Zhong Y, et al: Hypermorphic mutation of phospholipase C, g2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood 126:61-68, 2015
12. Thompson PA, O'Brien SM, Wierda WG, et al: Complex karyotype is a stronger predictor than del (17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 121:3612-3621, 2015
13. Byrd JC, Furman RR, Coutre SE, et al: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32-42, 2013
14. Maddocks K, Flynn JM, Andritsos L, et al: A phase II study of the BTK inhibitor ibrutinib in genetic risk-stratified relapsed and refractory patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). European Hematology Association Annual Meeting, Milan, Italy, June 12-15, 2014 (abstr S1343)
15. Jaglowski SM, Jones JA, Nagar V, et al: Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: A phase 1b/2 study. Blood 126:842-850, 2015